Candel Therapeutics, Inc.

NASDAQ:CADL

Biotechnology

Healthcare
$5.32 +0.56%

+$0.05 today

Market cap
$417.33M
Beta
-0.48
P/E (TTM)
-9.2
EPS (TTM)
-$0.87
52W Low $4.35High $9.57

Volume 1.39M

Average 1.82M

CADL Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Candel Therapeutics, Inc.NASDAQ: CADL

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was $0.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Gross Profit vs competitors

How CADL compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
CADL Competitors
Gross Profit for CADL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$212.73M USD+396.6%—98.0%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$201.75M USD+169.7%—53.2%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$169.15M USD+0.4%-0.5%74.5%
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M USD+16.2%-9.3%69.9%
CADLCandel Therapeutics, Inc.LTM Mar 2026$0 USD———
NBPNovaBridge BiosciencesLTM Sep 2025CN¥0 CNY+100.0%——
IMMXImmix Biopharma, Inc.LTM Mar 2026-$130.77K USD———
GNLXGenelux CorporationLTM Mar 2026-$284K USD-39.2%—3550.0%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026-$320K USD-5.3%——
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$29.86M USD-126.0%+164.4%—
Peer median (excluding CADL) —+8.3%-0.5%74.5%

Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue125K125K000
Cost of Revenue00000
Gross Profit125K125K000
Gross Margin100.0%100.0%———
Research & Development15.18M20.79M24.51M19.31M30.5M
Selling, General & Admin10.67M14.06M13.89M14.06M17.77M
Operating Expenses24.78M34.8M38.39M33.37M48.27M
Depreciation & Amortization232K778K960K990K845K
EBITDA(24.42M)(16.31M)(34.38M)(52.1M)(35.22M)
EBITDA Margin-19534.4%-13046.4%———
Operating Income(24.65M)(34.67M)(38.39M)(33.37M)(48.27M)
Operating Margin-19720.0%-27739.2%———
Interest Income01.22M2.08M1.09M3.92M
Interest Expense53K1.71M2.6M2.09M2.12M
Other Income / Expenses(10.4M)15.93M452K(21.81M)10.08M
Income Before Tax(36.12M)(18.79M)(37.94M)(55.18M)(38.18M)
Pre-Tax Margin-28899.2%-15035.2%———
Income Tax Expense00000
Net Income(36.12M)(18.79M)(37.94M)(55.18M)(38.18M)
Net Margin-28899.2%-15035.2%———
EPS (Basic)(1.26)(0.10)(1.31)(1.74)(0.72)
EPS (Diluted)(1.26)(0.10)(1.31)(1.74)(0.72)
Weighted Avg Shares28.69M28.82M28.94M31.68M52.96M
Weighted Avg Shares (Diluted)28.69M28.82M28.94M31.68M52.96M

Candel Therapeutics, Inc.

NASDAQ:CADL

Intrinsic Alpha fair value

Locked

Current Price

$5.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.